Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 17/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086320 | 0.84 | HRH3 (0.52) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL3091282 | 0.81 | HRH3 (0.60) | HRH3HRH1 | |
| SCHEMBL3090947 | 0.76 | HRH3 (0.53) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL3089295 | 0.76 | HRH3 (0.55) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL167108 | 0.76 | HRH3 (0.68) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL3086218 | 0.75 | HRH3 (0.52) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL1639622 | 0.75 | HRH3 (0.43) | HRH3HRH1OPRM1OPRD1 | |
| SCHEMBL3090791 | 0.74 | HRH3 (0.61) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL1638999 | 0.74 | HRH3 (0.44) | HRH3HRH1 | |
| SCHEMBL3091082 | 0.74 | ALDH1A1 (0.48) | HRH3HRH1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207331-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | claimed |
| US-7799773-B2 | Benzazepine derivatives for the treatment of neurological disorders | GLAXO GROUP LIMITED (GB) | 2010-09-21 | — | — | US | claimed |
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145040-A1 | Benzazepine Derivatives For The Treatment of Neurological Disorders | GRIN2C, GRIN2A, GRIN2B | HRH3 450/4885HRH1 947/4885OPRM1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.